The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period, according to a new report by Grand View Research, Inc. Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.
Increasing pool of market innovators such as 23andMe,Oxford Nanopore Technologies, and Veritas Genetics that have launched breakthrough genomic technologies in recent years are also contributing toward market development. 23andMe has expertise in developing direct-to-consumer genomic tests targeted toward disease prognosis and has recently received FDA approval for its commercialization.
MinION - a trademark sequencing device of Oxford Nanopore Technologies, is witnessing significant traction owing to its ability to sequence any fragment length of DNA in real time. On the other hand, Veritas Genetics offers an affordable solution for a complete readout of the genomic sequence. Earlier procured only by doctors, these tests can now be taken by anyone curious about their DNA and costs approximately USD 1,000. The company has also begun the commercialization of this technique for newborn’s genomic sequencing applications in China in 2017.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
The consumables and reagents deliverable segment is expected to register highest growth rate owing to high costs associated with specific essential reagents along with high volume requirement
The computational services deliverable segment is set to expand at a considerable CAGR from 2020 - 2027 owing to the increasing demand for computational sequence alignment and analysis among molecular biologists
Development of predictive biomarkers targeted toward diagnosis and monitoring and substantial investments by biotechnology and pharmaceutical companies have contributed significantly to the revenue generated by the biomarker discovery application segment in 2019
Asia Pacific is a potentially lucrative market for genomics and is anticipated to expand at the highest CAGR of 9.1%
Key players of genomics market include 23andMe; F. Hoffmann-La Roche Ltd.; BGI; Myriad Genetics Inc.; Danaher.; Pacific Biosciences; Illumina; Agilent Technologies; Thermo Fisher Scientific, Inc.; Foundation Medicine; Oxford Nanopore Technologies; and Bio-Rad Laboratories.
Grand View Research has segmented the global genomics market on the basis of deliverables, application and technology, end use, and region:
Genomics Deliverable Outlook (Revenue, USD Million, 2016 - 2027)
Instruments & Software
Consumables & Reagents
Core Genomics Services
Biomarker Translation Services
Genomics Application & Technology Outlook (Revenue, USD Million, 2016 - 2027)
Chromatin immunoprecipitation-sequencing (ChIP & ChIP-Seq)
Methylated DNA immunoprecipitation (MeDIP)
High resolution melt (HRM)
Chromatin accessibility assays
Proteomics tools (2-D PAGE; yeast 2-hybrid studies)
Genomics End-use Outlook (Revenue, USD Million, 2016 - 2027)
Clinical & Research Laboratories
Academic & Government Institutes
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Other End Users
Genomics Regional Outlook (Revenue, USD Million, 2016 - 2027)
Middle East and Africa (MEA)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."